Table 4.
Barriers to the return of IFs
| Barriers | Major barrier | Minor barrier |
|---|---|---|
| Uncertain clinical utility of IFs | 93 (83.0) | 19 (17.0) |
| Possibility that participants will misunderstand IFs | 73 (64.6) | 40 (35.4) |
| Potential for causing emotional harm to the study participants | 63 (55.8) | 50 (44.2) |
| Need to ensure access to trained clinician after disclosure of IFs | 70 (61.9) | 43 (38.1) |
| Potential for loss of confidentiality | 72 (63.7) | 41 (36.3) |
| Possibility that association with IFs may not be valid | 68 (60.7) | 44 (39.3) |
| Need to use a clinically certified lab | 75 (66.4) | 38 (33.6) |
| Concern about adequacy of clinical follow-up | 73 (64.6) | 40 (35.4) |
| Potential to distort the line between research and clinical care | 54 (47.8) | 59 (52.2) |
| Possibility of social discrimination | 65 (57.5) | 48 (42.5) |
| Concern over liability for adverse outcomes of IFs disclosure | 65 (57.5) | 48 (42.5) |
| Time commitment required to return IFs | 52 (46.0) | 61 (54.0) |
| Possibility that genotyping may be inaccurate | 75 (66.4) | 38 (33.6) |
| Need to keep contact patients information update | 56 (50.0) | 56 (50.0) |
| Need to keep up to date with relevant associations of IFs with the disease | 64 (56.6) | 49 (43.4) |
| Cost of returning IFs to participants | 64 (56.6) | 49 (43.4) |